AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16804654 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (Pip) plus aminoglycoside (AMG)
Number of subjects: 717
Study 16804654 — intervention group
Group type: COMPARATOR
Intervention: Third generation cephalosporin (Ceph) plus AMG
Number of subjects: 717
Study 16804654 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (Imi) plus glycopeptide (GLP)
Number of subjects: 717
Study 16804654 — intervention group
Group type: EXPERIMENTAL
Intervention: Imi/GLP plus amphotericin B deoxycholate (AmB) plus 5-flucytosine (5-FC)
Number of subjects: 717
Study 16804654 — intervention group
Group type: EXPERIMENTAL
Intervention: Imi/GLP plus fluconazole (Fluco)
Number of subjects: 717
Study 14550686 — intervention group
Group type: EXPERIMENTAL
Intervention: IV heroin maintenance treatment
Number of subjects: 25
Study 14550686 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methadone maintenance treatment
Number of subjects: 25
Study 14550686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11079510 — intervention group
Group type: COMPARATOR
Intervention: Noninjured cohort (C)
Number of subjects: 70
Study 8669677 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hyperbaric lidocaine with epinephrine (60 mg for arthroscopy or 75 mg for hernia repair)
Number of subjects: 159
Study 8669677 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% isobaric lidocaine without epinephrine (60 mg for arthroscopy or 75 mg for hernia repair)
Number of subjects: 159
Study 8669677 — intervention group
Group type: COMPARATOR
Intervention: 0.75% hyperbaric bupivacaine without epinephrine (7.5 mg for arthroscopy or 9.0 mg for hernia repair)
Number of subjects: 159
Study 8669677 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hyperbaric lidocaine with epinephrine
Number of subjects: 159
Study 8669677 — intervention group
Group type: COMPARATOR
Intervention: 0.75% hyperbaric bupivacaine
Number of subjects: 159
Study 8669677 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing arthroscopy
Number of subjects: 159
Study 8669677 — intervention group
Group type: COMPARATOR
Intervention: Patients undergoing hernia repair
Number of subjects: 159
Study 1303319 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 265
Study 1303319 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 265
Study 3897560 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg Oltipraz (single dose)
Number of subjects: 151
Study 3897560 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg Oltipraz (split dose)
Number of subjects: 151
Study 29574445 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiosk management
Number of subjects: 120
Study 29574445 — intervention group
Group type: COMPARATOR
Intervention: Nurse management
Number of subjects: 120
Study 27531573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride/acetaminophen combination (TRAM/APAP)
Number of subjects: 280
Study 27531573 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug (NSAID)
Number of subjects: 280
Study 23839330 — intervention group
Group type: EXPERIMENTAL
Intervention: Small stitches
Number of subjects: 691
Study 23839330 — intervention group
Group type: COMPARATOR
Intervention: Large stitches
Number of subjects: 691
Study 22213771 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 279
Study 22213771 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 279
Study 22213771 — intervention group
Group type: COMPARATOR
Intervention: Divalproex sodium
Number of subjects: 279
Study 20541573 — intervention group
Group type: EXPERIMENTAL
Intervention: High disinhibition
Number of subjects: 33
Study 20541573 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrained eaters
Number of subjects: 33
Study 20541573 — intervention group
Group type: COMPARATOR
Intervention: Restraint
Number of subjects: 33
Study 18951617 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk oral immunotherapy (OIT)
Number of subjects: 20
Study 18951617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15688279 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp120 vaccine
Number of subjects: 5403
Study 15688279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5403
Study 12549814 — intervention group
Group type: EXPERIMENTAL
Intervention: KP model
Number of subjects: 5499
Study 12549814 — intervention group
Group type: EXPERIMENTAL
Intervention: State model
Number of subjects: 5499
Study 12549814 — intervention group
Group type: COMPARATOR
Intervention: Control model
Number of subjects: 5499
Study 11236255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVH (35.8% in mild HT, 68.18% in moderate HT, 100% in severe HT)
Number of subjects: 121
Study 11236255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVH
Number of subjects: 121
Study 11236255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without LVH
Number of subjects: 121
Study 11236255 — intervention group
Group type: COMPARATOR
Intervention: Control group (39 healthy normotensives)
Number of subjects: 121
Study 8991490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilacor XR (180 mg d‐1)
Number of subjects: 0
Study 8991490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilacor XR (540 mg d‐1)
Number of subjects: 0
Study 8991490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilacor XR
Number of subjects: 0
Study 8991490 — intervention group
Group type: COMPARATOR
Intervention: Cardizem CD
Number of subjects: 0
Study 1318364 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet (200 mg/kg continuous infusion prior to 1988 or 60 mg/kg t.i.d. or 90 mg/kg b.i.d. intermittent infusion with saline hyperhydration)
Number of subjects: 66
Study 1318364 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 66
Study 6147838 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam (1.5 mg)
Number of subjects: 16
Study 6147838 — intervention group
Group type: EXPERIMENTAL
Intervention: flurazepam (30 mg)
Number of subjects: 16
Study 6147838 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam (30 mg)
Number of subjects: 16
Study 6147838 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 6147838 — intervention group
Group type: EXPERIMENTAL
Intervention: active drug conditions (lormetazepam, flurazepam, temazepam)
Number of subjects: 16
Study 6147838 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam
Number of subjects: 16
Study 6147838 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam
Number of subjects: 16
Study 6147838 — intervention group
Group type: EXPERIMENTAL
Intervention: active drugs
Number of subjects: 16
Study 6147838 — intervention group
Group type: EXPERIMENTAL
Intervention: flurazepam
Number of subjects: 16
Study 29743078 — intervention group
Group type: EXPERIMENTAL
Intervention: MIV‐711 (single oral doses from 20 to 600 mg in humans; 3‐30 µmol/kg in monkeys)
Number of subjects: 2
Study 29743078 — intervention group
Group type: EXPERIMENTAL
Intervention: MIV‐711 (repeat oral dosing)
Number of subjects: 2
Study 27916408 — intervention group
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine
Number of subjects: 454
Study 27916408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study 25117063 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight target
Number of subjects: 185
Study 25117063 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrollability (medical) information
Number of subjects: 185
Study 25117063 — intervention group
Group type: EXPERIMENTAL
Intervention: Average-weight target
Number of subjects: 185
Study 25117063 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant body image state
Number of subjects: 185
Study 24067387 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin with guaraná
Number of subjects: 20
Study 24067387 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin without guaraná
Number of subjects: 20
Study 24067387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21239190 — intervention group
Group type: EXPERIMENTAL
Intervention: AS195 (red-vine-leaf extract) 720 mg per day for 12 weeks
Number of subjects: 248
Study 21239190 — intervention group
Group type: EXPERIMENTAL
Intervention: AS195 (red-vine-leaf extract)
Number of subjects: 248
Study 21239190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 18496349 — intervention group
Group type: EXPERIMENTAL
Intervention: SpineCor (flexible spinal orthosis)
Number of subjects: 43
Study 18496349 — intervention group
Group type: COMPARATOR
Intervention: Rigid spinal orthosis
Number of subjects: 43
Study 17063001 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 50
Study 17063001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12728086 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-component acellular pertussis vaccine administered at birth (group 1)
Number of subjects: 91
Study 12728086 — intervention group
Group type: COMPARATOR
Intervention: 3-component acellular pertussis vaccine administered at 3, 5, and 11 months (group 2)
Number of subjects: 91
Study 10992828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 1 mg kg‐1
Number of subjects: 100
Study 10992828 — intervention group
Group type: COMPARATOR
Intervention: Oral ketoprofen 1 mg kg‐1
Number of subjects: 100
Study 10992828 — intervention group
Group type: COMPARATOR
Intervention: Both oral and i.v. placebo
Number of subjects: 100
Study 8776645 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (autologous fresh blood donated before bypass, cell saver and membrane oxygenator used)
Number of subjects: 150
Study 8776645 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (reinfused with autologous blood only)
Number of subjects: 150
Study 8776645 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (control group, blood remaining in the oxygenator reinfused)
Number of subjects: 150
Study 1727903 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 132
Study 1727903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 6384070 — intervention group
Group type: EXPERIMENTAL
Intervention: bepridil hydrochloride
Number of subjects: 13
Study 31399460 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily observed treatment
Number of subjects: 0
Study 31399460 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment dispensed every 2 weeks
Number of subjects: 0
Study 31399460 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment dispensed every 2 weeks with adherence psychological intervention
Number of subjects: 0
Study 28787749 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor scale
Number of subjects: 110
Study 28787749 — intervention group
Group type: COMPARATOR
Intervention: WHO partograph
Number of subjects: 110
Study 25477225 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperdense artery sign (HAS) on noncontrast CT
Number of subjects: 273
Study 25477225 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal arteries
Number of subjects: 273
Study 25477225 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal arteries
Number of subjects: 273
Study 25477225 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinner CT slices
Number of subjects: 273
Study 25477225 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of HAS
Number of subjects: 273
Study 24418726 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg intravenously, acute)
Number of subjects: 20
Study 24418726 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (2 g orally, prolonged)
Number of subjects: 20
Study 24418726 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled CO2 (1%-2%) during exercise
Number of subjects: 20
Study 24418726 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged acetazolamide at rest
Number of subjects: 20
Study 24418726 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum exercise after prolonged acetazolamide
Number of subjects: 20
Study 24418726 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight apnea/hypopnea index
Number of subjects: 20
Study 22851561 — intervention group
Group type: COMPARATOR
Intervention: Standard (conventional) fractionated radiotherapy (STRT) followed by chemotherapy
Number of subjects: 340
Study 22851561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HFRT) followed by chemotherapy
Number of subjects: 340
Study 22851561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (HFRT and STRT)
Number of subjects: 340
Study 19220307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan/Naproxen Sodium 85/500 mg (S/NS)
Number of subjects: 570
Study 19220307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 18077942 — intervention group
Group type: EXPERIMENTAL
Intervention: New hypodense lesion on the first postoperative day CT
Number of subjects: 156
Study 18077942 — intervention group
Group type: COMPARATOR
Intervention: No lesions on any follow-up CT scans
Number of subjects: 156
Study 18077942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion appearing later than the first postoperative morning
Number of subjects: 156
Study 15683159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine
Number of subjects: 304
Study 15683159 — intervention group
Group type: COMPARATOR
Intervention: Monovalent hepatitis A and hepatitis B vaccine
Number of subjects: 304
Study 15683159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 304
Study 11386781 — intervention group
Group type: EXPERIMENTAL
Intervention: Moulded metacarpal brace
Number of subjects: 73
Study 11386781 — intervention group
Group type: COMPARATOR
Intervention: Neighbour strapping
Number of subjects: 73
Study 9702948 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 42
Study 9702948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8994122 — intervention group
Group type: COMPARATOR
Intervention: High CSF lactate levels in MS patients during clinical exacerbation of relapsing‐remitting course
Number of subjects: 52
Study 8994122 — intervention group
Group type: COMPARATOR
Intervention: CSF lactate in MS patients with MRI evidence of Gd‐enhanced plaques
Number of subjects: 52
Study 8994122 — intervention group
Group type: COMPARATOR
Intervention: CSF lactate positivity in MS patients with clinical activity
Number of subjects: 52
Study 8994122 — intervention group
Group type: COMPARATOR
Intervention: CSF lactate positivity in MS patients with MRI enhancement
Number of subjects: 52
Study 8994122 — intervention group
Group type: COMPARATOR
Intervention: Elevated lactate signal in Gd‐enhanced plaques
Number of subjects: 52
Study 8994122 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased CSF lactate in patients with acute meningitis and idiopathic polyneuropathy
Number of subjects: 52
Study 8994122 — intervention group
Group type: COMPARATOR
Intervention: Decrease of CSF formulate levels in MS patients during active and inactive clinical phase
Number of subjects: 52
Study 8994122 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant increase of choline in acute plaques
Number of subjects: 52
Study 8994122 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease of N‐acetyl aspartate in chronic plaques
Number of subjects: 52
Study 8994122 — intervention group
Group type: COMPARATOR
Intervention: CSF glucose levels in bacterial meningitis
Number of subjects: 52
Study 2126437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 5 mg
Number of subjects: 306
Study 2126437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 306
Study 2126437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 306
Study 2126437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (all doses)
Number of subjects: 306
Study 2126437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 7211425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (1 to 2.6 mg per day)
Number of subjects: 10
Study 31958166 — intervention group
Group type: COMPARATOR
Intervention: Freehand surgery
Number of subjects: 101
Study 31958166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully guided surgery
Number of subjects: 101
Study 31958166 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot, partial, and full guided surgery protocols
Number of subjects: 101
Study 31640993 — intervention group
Group type: EXPERIMENTAL
Intervention: TiM telehealth plus usual care
Number of subjects: 40
Study 31640993 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 26765160 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm compress bistage intervention
Number of subjects: 150
Study 26765160 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 150
Study 23893418 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 40
Study 23893418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution) injection
Number of subjects: 40
Study 21880992 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 177
Study 21880992 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 177
Study 19552748 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg three times daily for 6 days)
Number of subjects: 13
Study 19552748 — intervention group
Group type: COMPARATOR
Intervention: Control phase (fexofenadine alone)
Number of subjects: 13
Study 16735920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic Dead Sea salt (DSS) solution
Number of subjects: 42
Study 16735920 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline
Number of subjects: 42
Study 15025782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in addition to usual standard of care)
Number of subjects: 1690
Study 11370224 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (PPI + three antibiotics)
Number of subjects: 0
Study 11370224 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (PPI + two antibiotics)
Number of subjects: 0
Study 9336372 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric remodeling patients
Number of subjects: 118
Study 8227112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mesoglycan (200 mg/day)
Number of subjects: 2
Study 8227112 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 2
Study 3801953 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide plus dexamethasone
Number of subjects: 36
Study 3801953 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 36
Study 3801953 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 36
Study 3801953 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide and Metoclopramide plus dexamethasone
Number of subjects: 36
Study 3801953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiemetic therapy
Number of subjects: 36
Study 3801953 — intervention group
Group type: EXPERIMENTAL
Intervention: Late nausea or vomiting
Number of subjects: 36
Study 31861922 — intervention group
Group type: EXPERIMENTAL
Intervention: Public hospitals
Number of subjects: 154
Study 31861922 — intervention group
Group type: COMPARATOR
Intervention: Private hospitals
Number of subjects: 154
Study 30028029 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 30
Study 30028029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 30
Study 30028029 — intervention group
Group type: COMPARATOR
Intervention: Comparison between RF and Cryoballoon groups
Number of subjects: 30
Study 27654572 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic tape
Number of subjects: 15
Study 27654572 — intervention group
Group type: COMPARATOR
Intervention: Sham tape
Number of subjects: 15
Study 27654572 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 15
Study 25046948 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling Capsule (WC), 0.33 g each pill, 3 pills per day, three times per day
Number of subjects: 110
Study 25046948 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 pills per day, three times per day
Number of subjects: 110
Study 25046948 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling Capsule (WC)
Number of subjects: 110
Study 25046948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 22892226 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention
Number of subjects: 176
Study 22892226 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study 19717327 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative therapy
Number of subjects: 146
Study 19717327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of movement
Number of subjects: 146
Study 17880761 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-15 treatment in vitro
Number of subjects: 0
Study 17880761 — intervention group
Group type: EXPERIMENTAL
Intervention: Controller group
Number of subjects: 0
Study 17880761 — intervention group
Group type: COMPARATOR
Intervention: Non-Controller group
Number of subjects: 0
Study 17880761 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-15 levels
Number of subjects: 0
Study 16213850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian biopsy in 10 women
Number of subjects: 266
Study 16213850 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with histologically confirmed autoimmune oophoritis
Number of subjects: 266
Study 16213850 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall testing for adrenal cortex autoantibodies
Number of subjects: 266
Study 11837554 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐284756 (400 mg) after a high-fat meal
Number of subjects: 14
Study 11837554 — intervention group
Group type: COMPARATOR
Intervention: BMS‐284756 (400 mg) in a fasted state
Number of subjects: 14
Study 10419911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse endoscopists
Number of subjects: 328